Exploration of key drug target proteins highlighting their related regulatory molecules, functional pathways and drug candidates associated with delirium: evidence from meta-data analyses

• Published in: BMC geriatrics Vol. 23; no. 1; p. 767
• Main Authors: Mosharaf, Md Parvez, Alam, Khorshed, Gow, Jeff, Mahumud, Rashidul Alam
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22-11-2023; BioMed Central; BMC
• Subjects: AKT1 protein; Analysis; Aspirin; Bioinformatics; Biology; Biomarkers; Candidates; Care and treatment; Central nervous system; Clinical trials; Data collection; Datasets; Delirium; Delirium - drug therapy; Diagnosis; DNA binding proteins; Drug development; Drug repurposing; Ephedrine; Gene expression; Gene Regulatory Networks; Genetic aspects; Geriatrics; Guanidine; Hub-proteins; Humans; Inflammation; Keywords; Literature reviews; MicroRNA; MicroRNAs; MicroRNAs - genetics; miRNA; Molecular modelling; Morbidity; Neuroprotection; Older people; Oxidative stress; p53 Protein; Pathophysiology; Protein interaction; Protein-protein interactions; Proteins; Proteomics; Senescence; Shigellosis; Signal transduction; Stat3 protein; Toxicogenomics; Transcription factors; Transcription Factors - genetics; Australia; Delirium; Drug repurposing; microRNA; Transcription factors; Hub-proteins
• ISSN: 1471-2318; 1471-2318
• DOI: 10.1186/s12877-023-04457-1

Delirium is a prevalent neuropsychiatric medical phenomenon that causes serious emergency outcomes, including mortality and morbidity. It also increases the suffering and the economic burden for families and carers. Unfortunately, the pathophysiology of delirium is still unknown, which is a major obstacle to therapeutic development. The modern network-based system biology and multi-omics analysis approach has been widely used to recover the key drug target biomolecules and signaling pathways associated with disease pathophysiology. This study aimed to identify the major drug target hub-proteins associated with delirium, their regulatory molecules with functional pathways, and repurposable drug candidates for delirium treatment.
We used a comprehensive proteomic seed dataset derived from a systematic literature review and the Comparative Toxicogenomics Database (CTD). An integrated multi-omics network-based bioinformatics approach was utilized in this study. The STRING database was used to construct the protein-protein interaction (PPI) network. The gene set enrichment and signaling pathways analysis, the regulatory transcription factors and microRNAs were conducted using delirium-associated genes. Finally, hub-proteins associated repurposable drugs were retrieved from CMap database.
We have distinguished 11 drug targeted hub-proteins (MAPK1, MAPK3, TP53, JUN, STAT3, SRC, RELA, AKT1, MAPK14, HSP90AA1 and DLG4), 5 transcription factors (FOXC1, GATA2, YY1, TFAP2A and SREBF1) and 6 microRNA (miR-375, miR-17-5, miR-17-5p, miR-106a-5p, miR-125b-5p, and miR-125a-5p) associated with delirium. The functional enrichment and pathway analysis revealed the cytokines, inflammation, postoperative pain, oxidative stress-associated pathways, developmental biology, shigellosis and cellular senescence which are closely connected with delirium development and the hallmarks of aging. The hub-proteins associated computationally identified repurposable drugs were retrieved from database. The predicted drug molecules including aspirin, irbesartan, ephedrine-(racemic), nedocromil, and guanidine were characterized as anti-inflammatory, stimulating the central nervous system, neuroprotective medication based on the existing literatures. The drug molecules may play an important role for therapeutic development against delirium if they are investigated more extensively through clinical trials and various wet lab experiments.
This study could possibly help future research on investigating the delirium-associated therapeutic target biomarker hub-proteins and repurposed drug compounds. These results will also aid understanding of the molecular mechanisms that underlie the pathophysiology of delirium onset and molecular function.